GlassScriptPhysician profile
Cassie Wells
NPI 1063170843
$2,074.04
in general payments reported to CMS, 2019-2025
29 companies · $1,387 in 2025
The $1,387 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $687 · 2025: $1,387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,074.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,074.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $224.48 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $182.60 | 2024-2025 | Rexulti |
| Lilly USA, LLC | $170.21 | 2024-2025 | Jardiance, Zepbound |
| Exact Sciences Corporation | $168.59 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $146.57 | 2024-2025 | Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $133.30 | 2024-2025 | Trintellix |
| Antares Pharma, INC. | $97.84 | 2024-2025 | Xyosted |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $88.83 | 2025 | Caplyta |
| Tris Pharma INC | $88.00 | 2024-2025 | Dyanavel Xr |
| Ardelyx, INC. | $84.68 | 2024-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $79.88 | 2024-2025 | |
| Axsome Therapeutics, INC. | $68.48 | 2025 | Auvelity |
| Corcept Therapeutics | $55.12 | 2025 | Korlym |
| Esperion Therapeutics, INC. | $53.52 | 2024-2025 | Nexletol |
| Novo Nordisk INC | $52.45 | 2025 | Ozempic, Rybelsus |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $50.35 | 2024-2025 | Azstarys |
| Tolmar, INC. | $46.54 | 2025 | Jatenzo |
| Pfizer INC. | $35.57 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.86 | 2024-2025 | Xifaxan |
| Dexcom, INC. | $31.56 | 2024-2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $26.42 | 2025 | Rexulti |
| Verity Pharmaceuticals INC. | $25.93 | 2025 | Tlando |
| Phathom Pharmaceuticals, INC. | $25.47 | 2024-2025 | Voquezna |
| Amgen INC. | $21.76 | 2025 | Krystexxa |
| Shield Therapeutics INC | $18.67 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $18.44 | 2024 | Austedo Xr |
| Merck Sharp & Dohme LLC | $16.21 | 2024 | Verquvo |
| Scilex Pharmaceuticals INC. | $15.04 | 2024 | |
| Glaxosmithkline, LLC. | $14.67 | 2025 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassie Wells listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.